John A. Romley, PhD

Altruism values for treatments of rare, severe pediatric diseases have not been estimated. This study found the altruism value for a hypothetical new Duchenne muscular dystrophy treatment to be $80 per year.

The degree to which novel value elements such as insurance value impact estimated treatment value for rare, severe genetic diseases such as Duchenne muscular dystrophy is unclear.

This study assesses the value of novel immuno-oncology treatments to society.

Across the US, adults with major medical conditions were less likely to die in hospitals with higher spending levels, even after adjusting for patient risk.

Stakeholders in US healthcare are increasingly seeking to measure and improve efficiency. This article describes an efficiency concept and some practical measurement challenges.